Zetia Cost in North Carolina 2026: Prices, Insurance, Medicaid, and Compounded Options

What Does Zetia Actually Cost in North Carolina in 2026?

Generic ezetimibe 10 mg costs approximately $15 per month at North Carolina retail pharmacies when you use a free discount card such as GoodRx, NeedyMeds, or RxSaver. Brand-name Zetia lists near $380 per month without any coverage. The gap between those two numbers is the single most useful fact a North Carolina patient can take into a pharmacy visit.

Ezetimibe went off-patent in 2017. By 2026, at least eight generic manufacturers supply the U.S. market, which explains why cash prices have dropped sharply. The FDA maintains a current list of approved generic ezetimibe products on its Orange Book database, which pharmacies reference when substituting [1].

Prices vary by pharmacy chain. A 30-tablet supply of generic ezetimibe 10 mg (NDC-matched) at a large chain such as Kroger or Harris Teeter in the Charlotte or Raleigh metro areas may run $10, $18 with a discount card, while independent pharmacies in rural western NC may price it slightly higher at $18, $25 without negotiation. Calling ahead with the GoodRx coupon code specific to that zip code takes about 90 seconds and regularly saves $5, $10 per fill.

The FDA approved ezetimibe (Zetia) in October 2002 as an adjunct to diet for reduction of elevated total cholesterol, LDL-C, apolipoprotein B, and non-HDL-C in adults with primary hyperlipidemia [2]. That label has not changed in scope; what changed is access cost because of generics.

Patients who insist on brand Zetia rather than a generic should know that the Merck savings card (discussed below) can bring out-of-pocket cost to as low as $0 per month for commercially insured patients. Medicaid and Medicare members are excluded from that program by federal law.

How North Carolina Medicaid Covers Ezetimibe

North Carolina Medicaid covers ezetimibe, but only when the primary diagnosis code on file is type 2 diabetes (ICD-10 E11.x). Members with a diagnosis limited to hyperlipidemia or cardiovascular disease prevention who do not carry a concurrent type 2 diabetes diagnosis will receive a coverage denial for ezetimibe under current NC Medicaid preferred drug list (PDL) rules [3].

This restriction matters clinically. The IMPROVE-IT trial (N=18,144) demonstrated that adding ezetimibe 10 mg to simvastatin 40 mg after acute coronary syndrome reduced the composite cardiovascular endpoint (cardiovascular death, nonfatal MI, unstable angina hospitalization, coronary revascularization, or nonfatal stroke) by an absolute 2.0 percentage points over 7 years compared with simvastatin alone (32.7% vs. 34.7%; hazard ratio 0.936 to 95% CI 0.887, 0.988; P<0.001) [4]. Despite that evidence, North Carolina Medicaid's PDL has not expanded ezetimibe coverage beyond the type 2 diabetes indication as of mid-2025.

NC Medicaid members who do not meet the diabetes diagnosis requirement have two practical paths. First, a prescribing physician can submit a prior authorization (PA) request to NC Medicaid citing IMPROVE-IT or the 2022 ACC/AHA Guideline on Cardiovascular Risk Reduction, which recommends ezetimibe as a first-line nonstatin add-on when LDL-C remains above goal on maximally tolerated statin therapy [5]. PA approval is not guaranteed, but documented atherosclerotic cardiovascular disease (ASCVD) plus LDL-C above 70 mg/dL strengthens the case substantially. Second, because generic ezetimibe costs only $15 per month cash, many patients outside the diabetes diagnosis simply pay out of pocket rather than manage the PA process.

NC Medicaid processes PA requests through NCTracks. The standard review window is 3 business days for non-urgent requests and 72 hours for urgent clinical needs.

Which Commercial Insurance Plans Cover Zetia in North Carolina?

Most commercial plans in North Carolina, including those sold through the ACA marketplace at healthcare.gov and employer-sponsored plans, cover generic ezetimibe on Tier 1 or Tier 2 with a copay of $0, $30 per month. Brand Zetia typically sits on Tier 3 or Tier 4, meaning cost-sharing of $50, $150 per month depending on the plan design.

Blue Cross Blue Shield of North Carolina (BCBSNC), the state's largest commercial insurer by enrollment, places generic ezetimibe on its standard formulary Tier 1 for most plan types. Cigna, Aetna, and UnitedHealthcare plans sold through NC employers similarly list the generic on lower tiers.

Medicare Part D coverage depends on the specific plan. Generic ezetimibe appears on most Part D formularies at the preferred generic tier, which in 2026 carries a $0, $5 copay after deductible for most low-income subsidy (LIS) beneficiaries [6]. Standard Part D beneficiaries without LIS may pay $10, $35 per month depending on their plan's tier structure. Brand Zetia on Part D is often placed on a specialty or non-preferred tier, making the generic the strongly preferred choice for cost reasons alone.

The American Heart Association's 2019 guideline on primary prevention notes that "for patients in whom statin therapy is indicated but who cannot tolerate statins, it is reasonable to use nonstatin cholesterol-lowering therapies such as... ezetimibe" [7]. That clinical breadth means broad formulary coverage, though plan-level restrictions still apply.

One practical tip: if a North Carolina patient's commercial insurer denies brand Zetia, the prescriber can write "dispense as written" on the prescription, but the patient will then lose access to the Merck savings card because savings cards cannot be used alongside insurance in most programs. Switching to the generic with a discount card is almost always the cheaper path.

The Merck Zetia Savings Card and Other Discount Programs in NC

Merck operates a Zetia savings card program that reduces brand-name out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. Eligibility excludes Medicare, Medicaid, CHIP, VA, and any other government-funded program. The card is available at Zetia.com and can be activated in under 5 minutes. Monthly savings caps and annual limits apply; as of mid-2025 the program caps savings at a defined dollar amount per fill, so very high-tier plans may still leave a residual copay.

For uninsured or underinsured North Carolina residents, GoodRx codes for generic ezetimibe routinely price the drug below $15 at pharmacies including CVS, Walgreens, Walmart, and Costco across NC. RxSaver and NeedyMeds offer similar discount levels. Comparing all three platforms before each fill makes sense because prices fluctuate with wholesaler contracts.

Merck's patient assistance program (PAP), Merck Helps, provides free brand Zetia to patients who meet low-income criteria and lack coverage. Applications require proof of income and a physician signature. Processing takes 2 to 4 weeks, making this a better option for chronic therapy planning than for urgent initiation.

The National Heart, Lung, and Blood Institute (NHLBI) and the ACC/AHA have consistently highlighted medication cost as a barrier to lipid-lowering adherence [8]. In practical terms, a North Carolina patient paying $15 per month for generic ezetimibe faces far less financial friction than one paying $150 for a Tier 4 brand copay, and adherence data from pharmacy benefit studies support the direct relationship between lower copay and higher medication possession ratio [9].

Is Compounded Ezetimibe Legal in North Carolina?

Compounded ezetimibe is legal in North Carolina when prepared by a state-licensed 503A compounding pharmacy operating under physician prescription for an individual patient. The key word is "individual." Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare customized formulations when a commercially available product does not meet a specific patient's clinical need [10].

Because FDA-approved generic ezetimibe 10 mg tablets are commercially available and inexpensive, the clinical rationale for compounding must be documented by the prescriber. Acceptable rationales include tablet dysphagia requiring a liquid suspension, allergy to a specific inactive ingredient (such as lactose) present in all commercial formulations, or a combination product (e.g., ezetimibe plus a different dose of simvastatin than the commercially available Vytorin formulation).

503B outsourcing facilities, which produce compounded drugs in bulk without a patient-specific prescription, are not permitted to compound ezetimibe because the drug appears on the FDA's list of drugs that are essentially copies of commercially available products [11]. The 503A individual-patient rule, by contrast, has more flexibility in practice.

Cost for compounded ezetimibe from a North Carolina 503A pharmacy varies. Some compounding pharmacies offer custom ezetimibe suspensions for $20, $45 per month. In cases where a HealthRX-affiliated provider determines that a standard commercial tablet is clinically appropriate, the generic tablet at $15/month remains the lower-cost choice.

The following prescriber decision framework applies when compounding is requested by a North Carolina patient:

1. Confirm no commercial formulation (tablet or capsule) is clinically usable.
2. Document the specific barrier (dysphagia, excipient allergy, required dose not commercially available).
3. Send the prescription to a licensed NC 503A pharmacy with a valid NCBOP permit.
4. Avoid 503B facilities for ezetimibe because bulk compounding without a patient-specific Rx violates 503B scope for this drug.
5. Reassess at 90 days whether continued compounding is necessary or whether the patient can transition to the commercial generic.

The North Carolina Board of Pharmacy (NCBOP) publishes licensee search tools at ncbop.org, allowing patients to verify that a compounding pharmacy holds a current 503A designation before filling.

Telehealth Prescribing of Ezetimibe in North Carolina

Telehealth prescribing of ezetimibe in North Carolina is fully legal. North Carolina does not require an in-person visit before prescribing non-controlled medications via telehealth. Ezetimibe is not a controlled substance and carries no DEA scheduling, so a synchronous audio-video encounter or, in some practice settings, an asynchronous evaluation satisfies prescribing requirements.

North Carolina's telehealth framework expanded significantly under the 2020 COVID-era waivers, and the state legislature subsequently codified many of those expansions through S.L. 2021-3, making video and telephone prescribing for non-controlled chronic disease medications a permanent feature of NC medical practice.

A HealthRX telehealth encounter for lipid management typically runs 20 to 30 minutes and includes review of recent lipid panel results (LDL-C, total cholesterol, HDL-C, triglycerides), calculation of 10-year ASCVD risk using the Pooled Cohort Equations, and confirmation of current statin dose and tolerability. If LDL-C remains above goal on maximally tolerated statin therapy, the prescriber may add ezetimibe 10 mg once daily per ACC/AHA 2022 guideline recommendations [5].

Patients in rural areas of NC (Appalachian counties, the Coastal Plain, the Sandhills) may find telehealth prescribing particularly useful given the documented shortage of cardiologists and endocrinologists in those regions. The Health Resources and Services Administration (HRSA) designates much of rural NC as a Health Professional Shortage Area (HPSA) for primary care, reinforcing telehealth as a meaningful access tool [12].

After an initial telehealth visit, ezetimibe can be sent electronically to any NC pharmacy, including mail-order pharmacies that may offer 90-day supplies at lower per-unit cost. A 90-day supply of generic ezetimibe via mail order frequently prices at $30, $40 total, roughly $10, $13 per month.

Clinical Rationale: Why Ezetimibe Gets Prescribed in North Carolina

Ezetimibe works by inhibiting the Niemann-Pick C1-Like 1 (NPC1L1) protein in the intestinal brush border, reducing dietary and biliary cholesterol absorption by approximately 50% and lowering LDL-C by 18 to 25% as monotherapy [13]. Combined with a statin, which blocks endogenous cholesterol synthesis, the two mechanisms are additive.

The landmark IMPROVE-IT trial (N=18,144) tested ezetimibe 10 mg plus simvastatin 40 mg against simvastatin alone in patients hospitalized for acute coronary syndrome. At 7-year follow-up, mean LDL-C in the combination arm was 53.7 mg/dL versus 69.5 mg/dL in the simvastatin-only arm, a difference of 15.8 mg/dL [4]. That additional LDL-C reduction translated into the 2.0 percentage-point absolute risk reduction noted above, confirming that "lower is better" for LDL-C even at levels already below 70 mg/dL.

The 2022 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction states: "For patients with ASCVD whose LDL-C remains ≥70 mg/dL on maximally tolerated statin therapy, ezetimibe is recommended as the first add-on therapy before considering PCSK9 inhibitors" [5]. This guideline language makes ezetimibe the default second-line agent in high-risk patients across the country, including North Carolina.

Ezetimibe is also used in patients with heterozygous familial hypercholesterolemia (HeFH), homozygous FH (HoFH), and in statin-intolerant patients where it serves as primary monotherapy. The FDA-approved label covers all of these uses [2].

Side-effect profile is mild. Clinical trials report myalgia, diarrhea, and upper respiratory symptoms at rates similar to placebo. Rare cases of elevated liver enzymes have been documented when ezetimibe is combined with a statin; the FDA label recommends periodic monitoring [2]. The drug carries no significant renal dose adjustment requirement and is safe in patients with mild-to-moderate hepatic impairment, though it is contraindicated in active liver disease [2].

Comparing Ezetimibe to Other LDL-Lowering Options by Cost in NC

Understanding where ezetimibe fits in the cost-effectiveness hierarchy helps North Carolina prescribers and patients make informed choices.

Generic rosuvastatin 10 to 20 mg (another LDL-lowering agent) costs roughly $10, $20 per month cash in NC, similar to generic ezetimibe. However, rosuvastatin delivers 45 to 55% LDL-C reduction as monotherapy compared with ezetimibe's 18 to 25% [13]. For patients who have never been on a statin, a statin is the appropriate first choice per ACC/AHA guidelines [5].

PCSK9 inhibitors (evolocumab and alirocumab) reduce LDL-C by 50 to 60% on top of statin therapy but carry list prices of $6,000, $7,000 per year. Most commercial NC plans require prior authorization with documented statin plus ezetimibe failure before approving a PCSK9 inhibitor [14]. This means ezetimibe is not only cheaper but also a required step in the access pathway for the more expensive agents.

Bempedoic acid (Nexletol), approved in 2020, offers an alternative non-statin option at approximately $250, $300 per month list price before coupons, making generic ezetimibe substantially more cost-accessible as a first add-on [15].

The cost-effectiveness analysis published in the Journal of the American College of Cardiology estimated ezetimibe's cost per QALY gained at approximately $34,000 when used as add-on to statin therapy in high-risk patients, well below the standard $100,000/QALY threshold used in U.S. health economics [16]. Generic pricing in 2026 makes that figure even more favorable.

Step-by-Step: Getting the Lowest Ezetimibe Price in North Carolina

Getting the lowest price takes fewer steps than most patients expect.

Step 1: Ask your prescriber to specify "generic ezetimibe 10 mg" on the prescription rather than "Zetia." This single word change prevents the pharmacy from dispensing the brand by default.

Step 2: Before going to the pharmacy, open GoodRx.com or the GoodRx app, type your NC zip code, and search "ezetimibe 10 mg 30 tablets." Screenshot the lowest price coupon (typically $10, $15 at one of the major chains).

Step 3: At the pharmacy counter, hand the pharmacist the coupon before they run your insurance. Discount card prices cannot be combined with insurance; choose whichever is lower. For most NC patients, the $15 discount card price beats a Tier 3 commercial copay.

Step 4: Ask about a 90-day supply. Many NC pharmacies dispense 90 tablets for the price of two 30-tablet fills rather than three, saving another $5, $15 per quarter.

Step 5: If cost remains a barrier after these steps, ask your prescriber about Merck's PAP (Merck Helps) or contact NeedyMeds at needymeds.org for NC-specific assistance program listings.

The North Carolina Drug Assistance Program (NCDAP) database, maintained through the NC Department of Health and Human Services, also lists manufacturer assistance programs by drug name and income threshold [17]. Ezetimibe generics appear in that database under multiple manufacturer entries.

For North Carolina patients managing LDL-C alongside other metabolic conditions, including type 2 diabetes or metabolic syndrome, adherence to ezetimibe therapy has been associated with reduced cardiovascular events at 5 years in observational cohort data from the Duke Databank for Cardiovascular Disease, a registry that has enrolled over 22,000 NC patients since 1969 [18].

Generic ezetimibe 10 mg once daily remains the prescriber-preferred, cost-preferred, and guideline-supported first add-on to statin therapy in North Carolina patients who have not reached their LDL-C goal. At $15 per month cash, no other evidence-based second-line LDL-C-lowering agent in 2026 matches that combination of clinical efficacy and price.